Share Price | Enhabit, Inc. Stock Analysis & Recommendation

Q: How big is Enhabit, Inc.?

Market Cap: As of Jun 18, Enhabit, Inc. has a market capitalization of 485.11 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Enhabit, Inc. reported net sales of 1,032.30 million and a net profit of -136.50 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 523.50 million and total assets of 1,252.20 million.

Q: What does Enhabit, Inc. do?

Overview:Enhabit, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.Financial Snapshot:- Most recent Net Sales: 260 Million (Quarterly Results - Mar 2025)- Most recent Net Profit: 18 Million (Quarterly Results - Mar 2025)- Market cap: USD 485.11 Million (Micro Cap)Key Metrics:- P/E: 22.00- Debt Equity: 0.84- Return on Equity: 4.64%- Price to Book: 0.89Contact Details:No Company Details Available.

Q: Is Enhabit, Inc. overvalued or undervalued?

As of 9 August 2023, the valuation grade for Enhabit, Inc. has moved from expensive to risky, indicating a shift in perception regarding its valuation. The company appears to be overvalued based on its current metrics, with a P/E ratio of 22, which is significantly higher than its peer Fulgent Genetics, Inc., which has a negative P/E of -21.28. Additionally, Enhabit’s EV to EBITDA stands at 12.62, while its peer shows a negative ratio of -8.07, further emphasizing the relative overvaluation.In comparison to the broader market, Enhabit has underperformed against the S&P 500, with a year-to-date return of 3.2% compared to the S&P's 12.22%. This trend is also reflected in the three-year return, where Enhabit declined by 45.87% versus the S&P's gain of 70.41%. Overall, the combination of high valuation ratios and poor stock performance suggests that Enhabit, Inc. is currently overvalued in the market.

Q: Is Enhabit, Inc. technically bullish or bearish?

As of 19 August 2025, the technical trend for Enhabit, Inc. has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD also shows mild bullishness. However, the Bollinger Bands and moving averages on the daily and weekly time frames are mildly bearish. The KST is bearish on the weekly, and the OBV is bearish on the monthly. In terms of performance, Enhabit has underperformed the S&P 500 across multiple periods, with a year-to-date return of 3.2% compared to the S&P 500's 12.22%, and a one-year return of -1.23% against the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish, driven by mixed signals across various indicators.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

146.55 k

Shareholding (Dec 2025)

FII

20.22%

Held by 78 FIIs

DII

33.16%

Held by 44 DIIs

Promoter

9.41%

How big is Enhabit, Inc.?

22-Jun-2025

As of Jun 18, Enhabit, Inc. has a market capitalization of 485.11 million, with net sales of 1,032.30 million and a net profit of -136.50 million over the latest four quarters. The company reported shareholder's funds of 523.50 million and total assets of 1,252.20 million as of Dec 24.

View full answer

What does Enhabit, Inc. do?

22-Jun-2025

Enhabit, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, with recent net sales of $260 million and a net profit of $18 million. It has a market cap of $485.11 million and key metrics include a P/E ratio of 22.00 and a debt equity ratio of 0.84.

View full answer

Is Enhabit, Inc. overvalued or undervalued?

20-Sep-2025

As of August 9, 2023, Enhabit, Inc. is considered overvalued with a P/E ratio of 22 and an EV to EBITDA of 12.62, underperforming the S&P 500 with a year-to-date return of 3.2% compared to the S&P's 12.22%.

View full answer

Is Enhabit, Inc. technically bullish or bearish?

20-Sep-2025

As of August 19, 2025, Enhabit, Inc. shows a mildly bearish trend with mixed technical indicators, underperforming the S&P 500 year-to-date and over the past year.

View full answer

Compare Enhabit, Inc. with Similar Stocks

Fulgent Genetics, Inc.Pediatrix Medical Group, Inc.OPKO Health, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 30.30

Healthy long term growth as Net Sales has grown by an annual rate of 301.12% and Operating profit at 79.91%

Positive results in Jun 25

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 690 Million (Micro Cap)

P/E

16.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.73

Return on Equity

7.71%

Price to Book

1.22

Revenue and Profits:

Net Sales:

265 Million

(Quarterly Results - Mar 2026)

Net Profit:

20 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

23.9%

6 Months

73.46%

1 Year

42.31%

2 Years

42.16%

3 Years

2.22%

4 Years

0.0%

5 Years

0.0%

Enhabit, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

301.91%

EBIT Growth (5y)

88.43%

EBIT to Interest (avg)

30.30

Debt to EBITDA (avg)

4.48

Net Debt to Equity (avg)

0.84

Sales to Capital Employed (avg)

0.92

Tax Ratio

1.87%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

6.10%

ROE (avg)

6.17%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.22

EV to EBIT

17.82

EV to EBITDA

12.64

EV to Capital Employed

1.13

EV to Sales

1.05

PEG Ratio

0.02

Dividend Yield

ROCE (Latest)

6.32%

ROE (Latest)

7.71%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

Bearish

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 42 Schemes (37.13%)

Foreign Institutions

Held by 78 Foreign Institutions (20.22%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is -2.07% vs 2.58% in Dec 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 151.96% vs -430.17% in Dec 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "264.80",
          "val2": "270.40",
          "chgp": "-2.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "33.90",
          "val2": "19.40",
          "chgp": "74.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "10.00",
          "val2": "7.60",
          "chgp": "31.58%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-47.70",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "19.90",
          "val2": "-38.30",
          "chgp": "151.96%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "110.60%",
          "val2": "53.30%",
          "chgp": "5.73%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 2.44% vs -1.10% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 98.31% vs -94.94% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,060.00",
          "val2": "1,034.80",
          "chgp": "2.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "86.30",
          "val2": "78.10",
          "chgp": "10.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "34.00",
          "val2": "41.70",
          "chgp": "-18.47%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-47.70",
          "val2": "-161.70",
          "chgp": "70.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.60",
          "val2": "-154.00",
          "chgp": "98.31%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "60.20%",
          "val2": "45.00%",
          "chgp": "1.52%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ

Mar'26

Dec'25

Change(%)

Net Sales

264.80

270.40

-2.07%

Operating Profit (PBDIT) excl Other Income

33.90

19.40

74.74%

Interest

10.00

7.60

31.58%

Exceptional Items

0.00

-47.70

100.00%

Consolidate Net Profit

19.90

-38.30

151.96%

Operating Profit Margin (Excl OI)

110.60%

53.30%

5.73%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Mar 2026 is -2.07% vs 2.58% in Dec 2025

Consolidated Net Profit

QoQ Growth in quarter ended Mar 2026 is 151.96% vs -430.17% in Dec 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

1,060.00

1,034.80

2.44%

Operating Profit (PBDIT) excl Other Income

86.30

78.10

10.50%

Interest

34.00

41.70

-18.47%

Exceptional Items

-47.70

-161.70

70.50%

Consolidate Net Profit

-2.60

-154.00

98.31%

Operating Profit Margin (Excl OI)

60.20%

45.00%

1.52%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 2.44% vs -1.10% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 98.31% vs -94.94% in Dec 2024

All Annual Results

Company CV

About Enhabit, Inc.

Enhabit, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available